A clinical trial of MK-4605 in healthy participants (MK-4605-001)
This study is an early-stage clinical trial for a new medicine called MK-4605. The drug is being developed as a possible treatment for dementia, a condition that affects memory and thinking. Before a medicine can be tested in patients, scientists must check how safe it is in healthy people. This is a 'first-in-human' Phase 1 trial. Researchers want to learn what doses are safe and how the body handles the medicine. The trial is looking for healthy men aged 18 and over to take part. Participants will be closely watched by a team of doctors and nurses. Healthy volunteers will not receive any medical benefit for their own health, but their involvement is a crucial step in testing whether this medicine could help people with dementia in the future.
At a glance
What is this study about?
Dementia is a term used to describe a range of conditions that cause problems with memory, thinking, and daily life. Scientists around the world are working hard to develop new treatments. Before any new medicine can be given to patients living with dementia, it must go through careful testing in clinical trials to ensure it is safe to use.
This trial is testing an experimental medicine named MK-4605. It is known as a Phase 1 or 'first-in-human' study. This means it is the very first time the medicine is being given to people after being tested in laboratories. The main goal at this stage is not to cure or treat dementia, but to understand if the drug is safe and well tolerated by the human body.
To make the test as clear as possible, early studies usually involve healthy volunteers rather than people who are unwell. Doctors will check how the drug moves through the body, how it is broken down, and whether it causes any unwanted side effects. Testing healthy volunteers helps doctors learn about the medicine without the confusion of other medical conditions or treatments.
Taking part in early research like this helps build the foundation for future medicines. Without the help of healthy volunteers, it would not be possible to discover and develop new treatments for conditions like dementia.
Key takeaways
- This is a Phase 1 clinical trial testing a new drug, MK-4605, for the first time in humans.
- The medicine is designed for dementia, but this trial only involves healthy volunteers.
- The study aims to check the safety and behaviour of the drug in the human body.
- Only men aged 18 and over who are in good general health can take part.
- Participation involves medical tests, clinic visits, and close health monitoring.
Who may be eligible?
This trial is specifically looking for healthy adult men aged 18 and over. Because this is the very first time the drug is given to humans, researchers need volunteers who do not have serious long-term health conditions.
Women cannot take part in this particular study. People who already have dementia or memory problems are also not eligible, as the focus is solely on seeing how the medicine affects a healthy body.
Before anyone can join, the research team will carry out health screening tests. These checks ensure that volunteers are in good health and that taking part is as safe as possible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am a man aged 18 or older.
- I consider myself to be in good overall health.
- I do not have a diagnosis of dementia or memory loss.
- I do not have major long-term illnesses or heart problems.
- I am willing to attend clinic visits and undergo health tests like blood draws.
What does participation involve?
If you decide to take part, you will first visit the trial clinic for a health check to make sure you are suitable. This may involve blood tests, urine tests, heart checks (ECGs), and checking your blood pressure. If you are eligible, you will receive either a single dose or several doses of MK-4605. You may need to stay at the clinic for one or more nights, or attend multiple day visits, so that the medical team can monitor your health closely. Blood and urine samples will be taken at set times to measure the medicine in your body. After the dosing period is complete, you will have follow-up visits to ensure you feel well. The total duration of the study usually lasts from a few weeks to a couple of months.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
Why is a dementia drug being tested on healthy people?
Testing healthy people first allows doctors to check the safety and side effects of the medicine without interference from other illnesses or treatments.
What does a 'first-in-human' trial mean?
It means this is the very first time the medicine has ever been given to people, following laboratory and animal safety checks.
Will taking this medicine protect me from getting dementia?
No. The medicine is being given at small doses simply to test its safety, and it will not protect you against dementia.
Do I have to pay for the trial?
No, you do not pay to take part. In Phase 1 trials, healthy volunteers are usually compensated for their time and travel expenses.
Can I leave the study if I feel uncomfortable?
Yes. Taking part is completely voluntary, and you have the right to withdraw at any point without it affecting your normal medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.